FTC settlement with CVS Health targets insulin pricing practices tied to its pharmacy benefit management business

The Federal Trade Commission announced a settlement with CVS Health’s pharmacy benefit manager business involving insulin prices, according to a report published Tuesday. The FTC framed the case as part of its broader focus on drug pricing practices and the role PBMs can play in what patients pay for medications.

CVS Health is a major operator in the U.S. health sector, with a business that includes PBM services. PBMs generally sit between drug manufacturers, pharmacies, and employers or insurers, handling pricing, formulary placement (which drugs are covered), and benefit design. The FTC’s action suggests the agency is continuing to scrutinize how those arrangements affect prices at the point of sale.

The report said the settlement is the FTC’s second major agreement this year with drug-industry middlemen. In this context, “middlemen” typically refers to entities that manage parts of the prescription drug supply chain beyond the manufacturer and the dispenser, including PBMs and other intermediaries.

CVS Health did not disclose additional settlement terms in the brief coverage, such as whether monetary relief was involved, how broad the conduct was alleged to be, or whether there are operational changes specified in the agreement. The FTC’s settlement also was not described in the reporting with enough detail to determine which specific insulin pricing practices were at issue beyond the general linkage to insulin pricing.

For CVS Health, any action involving its PBM unit matters because PBM operations are central to how beneficiaries access drugs and how net pricing is determined across the system. Even when investigations do not result in new rules for the entire industry, settlements can lead to compliance changes that may affect pharmacy networks, contracting terms, and how coverage lists are managed.

More broadly, the FTC’s stated focus reflects persistent political and regulatory pressure on drug pricing, particularly around insulin, which has been the subject of intense scrutiny for years due to wide price dispersion and affordability concerns. Regulatory attention on insulin through PBMs also fits a pattern of enforcement and investigations aimed at the incentives, billing practices, and pricing mechanics that can influence patient costs.

What remains unclear from the Tuesday coverage is the timeline of the alleged conduct, the exact insulin products or benefit designs implicated, and the specific remedies the settlement requires. Without those particulars, it is not possible to gauge the settlement’s financial impact on CVS Health or how quickly it would change insured consumers’ insulin out-of-pocket prices.

The next thing to watch is whether the FTC publishes additional details about the settlement terms and whether CVS Health provides further disclosure in connection with its PBM compliance and pricing practices. Observers will also likely look for any follow-on enforcement steps by federal or state regulators in the insulin-and-PBM space as the year’s pattern of agency actions continues.